Financial Report
1 January - 31 December
|
kEUR |
Note |
2021 |
2020 |
|
|
|
|
|
|
Revenue |
3 |
282,126 |
223,033 |
|
Other operating income |
3 |
4,091 |
1,778 |
|
Total income |
|
286,217 |
224,811 |
|
|
|
|
|
|
Cost of sales |
|
-182,426 |
-151,108 |
|
Gross profit |
|
103,791 |
73,703 |
|
|
|
|
|
|
Marketing and sales expenses |
3 |
-3,864 |
-3,640 |
|
Research expenses |
3 |
-1,407 |
-1,312 |
|
General and administrative expenses |
3 |
-34,355 |
-24,373 |
|
Total operating expenses |
|
-39,626 |
-29,325 |
|
|
|
|
|
|
Operating result (EBIT) |
|
64,165 |
44,378 |
|
|
|
|
|
|
Financial income |
3 |
653 |
106 |
|
Financial expenses |
3 |
-4,970 |
-6,799 |
|
Total financial result |
|
-4,317 |
-6,693 |
|
|
|
|
|
|
Result before income taxes |
|
59,848 |
37,685 |
|
|
|
|
|
|
Income tax charges |
5 |
-12,590 |
-6,350 |
|
Result for the year |
|
47,258 |
31,335 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
47,258 |
31,335 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
7 |
1.47 |
1.04 |
|
Earnings per share in EUR, diluted |
7 |
1.47 |
1.04 |